本帖最后由 老马 于 2012-1-13 21:20 编辑
5 B% I4 E$ R/ @) g0 B
- v5 n1 H9 |$ [1 X爱必妥和阿瓦斯丁的比较2 q0 D8 |6 }6 d
% p: ~+ F, b) v4 ^+ ^, W+ J
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 F7 e6 H3 A/ B& Q3 e) M5 z
6 b y7 ]# M& f+ h" e2 g; ?: F/ x
% E7 b2 E& c! {http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, o# p/ h* g( W* t==================================================: H% W& B* K( T, M9 F j2 `
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) N- Y/ `* R8 e( D2 Z5 aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 y7 x% H2 \$ [6 X9 i) J hResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 m! a) ]8 s, Q+ f
|